▲ Peaking
Business
Eli Lilly CEO reveals astonishing shift in GLP-1 pill market
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly
39 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
The company behind a new GLP-1 pill is betting $6.5 billion on Houston
12 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Eli Lilly is breaking ground in Houston on a facility planned for 2030
Eli Lilly plans a 2030 groundbreaking in Houston as weight-loss drug developers line up to tap a lucrative and increasingly competitive market.
◼ Archived
Health
Novo Nordisk (NVO) and Eli Lilly (LLY)’s Weight-Loss Drugs Still Work at Smaller Doses, Study Finds
Recent studies indicate that popular weight-loss treatments manufactured by Novo Nordisk and Eli Lilly retain efficacy at reduced doses.
◼ Archived
Business
🔮 fades ✓
Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly
Novartis experiences a trial failure with pelacarsen, impacting the Dow and raising questions for competitors like Amgen and Lilly.
◼ Archived
Business
🔮 fades ✗
Cholesterol drug setback casts doubt over multibillion-dollar race
A failed Novartis clinical trial for a cholesterol drug has triggered a biopharma selloff and cast doubt on competing efforts by Amgen and Eli Lilly.
◼ Archived
Business
🔮 fades ✓
Dairy company Chobani announces $1.2B investment in Pennsylvania
Chobani announces a $1.2 billion investment plan in Pennsylvania, boosting the Lehigh Valley economy according to recent coverage.
◼ Archived
Business
🔮 fades ✗
Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Eli Lilly to Buy Merida Biosciences for Up to $2.875 Billion
Eli Lilly is expanding its autoimmune portfolio through the acquisition of Merida Biosciences in a deal valued at up to $2.875 billion.
◼ Archived
Business
🔮 fades ✓
Why some companies may not be offering coverage for GLP-1 weight loss drugs
Corporate insurance coverage for GLP-1 weight-loss drugs is declining as companies like PepsiCo remove these benefits to manage pharmacy costs.
◼ Archived
Business
🔮 fades ✗
Eli Lilly Launches Foundayo Weight-Loss Pill in U.K.
Eli Lilly has introduced Foundayo, a new daily oral weight-loss medication, to the United Kingdom market, driving a significant rise in company stock.
◼ Archived
Business
🔮 fades ✗
FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly
The FDA has granted clearance to a first-of-its-kind blood test for Alzheimer's biomarkers developed through a partnership between Roche and Eli Lilly.
◼ Archived
Health
🔮 fades ✗
Researchers examine unanticipated benefits of GLP-1 medications
Researchers are investigating unexpected health benefits of GLP-1 medications as the drugs evolve beyond their primary use for weight loss.
◼ Archived
Business
🔮 fades ✓
Eli Lilly is suing six companies over illegal sales of its unapproved weight loss drug
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Eli Lilly takes aim at illicit market for its experimental weight-loss drug
Eli Lilly targets the illicit market for its unapproved obesity drug retatrutide through new legal actions.
◼ Archived
Health
🔮 fades ✓
UK approves its second weight-loss pill while EU access lags
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✗
Lilly's weight-loss pill gets UK regulator's nod
The UK medicines regulator has approved a new once-daily weight-loss pill from Eli Lilly, offering an oral alternative to injectable GLP-1 treatments.
◼ Archived
Business
🔮 fades ✗
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
Novo Nordisk’s once‑dominant GLP‑1 weight‑loss line now faces a fierce showdown with Eli Lilly, sparking questions about Europe’s biotech edge.
◼ Archived
Business
🔮 fades ✗
Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
Eli Lilly’s 48% revenue surge eclipses a weak earnings report from The Trade Desk, reshaping market expectations for biotech and ad tech alike.
◼ Archived
Business
🔮 fades ✓
Novo outlook hike falls flat as Wegovy pill sales fail to impress
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
Options market braces for $225 billion swing in SpaceX's value as earnings loom
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Novo Nordisk shares slide after guidance disappoints investors
Novo Nordisk shares decline despite Q2 profit beats and raised forecasts, amid intensifying competition with Eli Lilly.
◼ Archived
Business
🔮 holds ✓
Eli Lilly to allow more patients to apply for special access to unapproved obesity drug
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
This Billionaire Made $360 Million Selling His Psychedelic Company To Eli Lilly
Eli Lilly has expanded its neuropsychiatric portfolio through a multi-billion dollar acquisition of Atai, a psychedelic research company.
◼ Archived
Business
🔮 fades
Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average
Eli Lilly's retatrutide shows significant weight loss results in Phase 3 trials, paving the way for a 2027 FDA approval filing.
◼ Archived
Business
🔮 fades
Eli Lilly’s Next-Generation Weight-Loss Shot Clears Another Hurdle
Eli Lilly targets a first-quarter 2027 FDA application for its next-generation obesity drug retatrutide.
◼ Archived
Business
🔮 fades
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
Eli Lilly is moving toward 2027 regulatory filings for retatrutide after successful Phase 3 obesity trials showing significant weight and A1C improvements.
◼ Archived
Business
🔮 holds
Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Novo Nordisk has filed a lawsuit against Eli Lilly over allegations of deceptive and misleading advertising regarding GLP-1 weight-loss drugs.
◼ Archived
Business
🔮 fades
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo Nordisk has launched a legal offensive against Eli Lilly, alleging that the competitor's GLP-1 weight-loss drug advertising is deceptive.
◼ Archived
Business
🔮 fades
‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
Eli Lilly's $3.8 billion acquisition of AtaiBeckley signals a major shift as Big Pharma begins to validate the psychedelic medicine sector.
◼ Archived
Health
🔮 fades
The Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo?
FDA’s new peptide panel sparks regulatory debate as biotech giants Lilly and Novo eye the next health wave.
◼ Archived
Business
🔮 fades
Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports
Eli Lilly is entering the psychedelic drug market with a deal to acquire AtaiBeckley for up to $3.8 billion to treat resistant depression.
◼ Archived
Business
🔮 fades
Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Scribe Therapeutics seeks $75 million in an IPO, testing market appetite for early-stage biotech.
◼ Archived
Business
🔮 fades
FDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug Manufacturing
The FDA has launched the PreCheck pilot program with seven participants to accelerate and strengthen the domestic manufacturing of drugs in the United States.
◼ Archived
Business
🔮 fades
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026
The European Medicines Agency has issued a positive opinion recommending the approval of Eli Lilly's Jaypirca for chronic lymphocytic leukemia.
◼ Archived
Health
🔮 fades
Eli Lilly and Company (LLY) CEO on How GLP-1s Will Reshape America
Oral GLP-1 medications are gaining attention as clinical data emerges regarding their efficacy in weight management and potential to shift treatment paradigms.
◼ Archived
Business
🔮 fades
Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’
Eli Lilly reports positive initial Phase 1 clinical data for its $2.3 billion acquisition of Ajax Therapeutics' myelofibrosis treatment.